LSL Pharma Group (TSXV:LSL) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


TSXV:LSL LSL Pharma Group Inc TSXV:LSL
49 GF Score
Price C$0.32
GF Value C$0.72
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is LSL Pharma Group Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

LSL Pharma Group's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

TSXV:LSL vs ZTS: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, LSL Pharma Group's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LSL Pharma Group Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, LSL Pharma Group's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where LSL Pharma Group's Margin of Safety % (DCF Earnings Based) falls into.


TSXV:LSL
49GF Score
LSL Pharma Group Inc TSXV:LSL
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is LSL Pharma Group (TSXV:LSL) Overvalued in 2026?

Based on GuruFocus' analysis, LSL Pharma Group stock appears to be undervalued. The current stock price of C$0.32 is trading 55.6% below its estimated GF Value™ of C$0.72. GuruFocus considers LSL Pharma Group to be Possible Value Trap.

Key valuation signals for TSXV:LSL:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: C$0.72 vs. price of C$0.32 (55.6% below fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the TSXV:LSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

LSL Pharma Group Business Description

Address 540, rue d\'Avaugour, Bureau 1800, Boucherville, QC, CAN, J4B 0G6
LSL Pharma Group Inc develops, manufactures and commercializes sterile pharmaceutical products, cosmetic products and natural health products. It operates in three segments CMO activities include four operating entities LSL Laboratory, Dermolab, Du-Var, and VSI; Integrated Eye-care pharmaceutical company which includes sterile Eye-care manufacturing operation; and Private Label Business includes Juno OTC which commercializes pharmaceutical products with a focus on private label, over the counter (OTC) products. It derives majority of revenue from CMO activities segment.
49GF Score

Get the complete analysis for TSXV:LSL

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.32
Price
C$0.72
GF Value